03/05
Headlines

SNTA

Small Cap Bullish Stocks: Ardelyx (NASDAQ:ARDX), CDI (NYSE:CDI), Alliance Fiber Optic Products (NASDAQ:AFOP), Synta Pharmaceuticals (NASDAQ:SNTA), Fortuna Silver Mines (NYSE:FSM)

Kristen Barton03 mins

Ardelyx Inc (NASDAQ:ARDX) major shareholder Ventures Vii Lp Cmea bought 316,826 shares of Ardelyx stock on the open market in a transaction that occurred on Tuesday, June 24th. The shares were purchased at an average price of $14.00 per share, for a total transaction of $4,435,564.00. Ardelyx Inc (NASDAQ:ARDX) stock performance was 5.14% in last…

Read More

NASDAQ Recent Insider Buying: Synta Pharmaceuticals (NASDAQ:SNTA), Repligen Corporation (NASDAQ:RGEN), Equinix Inc (NASDAQ:EQIX), AspenBio Pharma (NASDAQ:APPY)

Colin Pettis02 mins

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Director Kovner Bruce purchased 1,250,000 shares of the stock in a transaction that occurred on Friday, April 11th. The shares were purchased at an average cost of $4.01 per share, with a total value of $5,012,500.00. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stock performance was 1.01% in last session and finished the day…

Read More

Investor’s Alert: Inovio Pharmaceuticals (NYSEMKT:INO), Synta Pharmaceuticals (NASDAQ:SNTA), Repligen Corporation (NASDAQ:RGEN), Agios Pharmaceuticals (NASDAQ:AGIO)

John Bellich02 mins

Inovio Pharmaceuticals Inc (NYSE:INO) CEO Jong Joseph Kim bought 25,000 shares of the company’s stock in a transaction dated Tuesday, April 15th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $56,250.00. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -2.62% in last session and finished the day…

Read More

Healthcare Bullish Stocks: Synta Pharmaceuticals (NASDAQ:SNTA), TherapeuticsMD Inc (NYSEMKT:TXMD), Cell Therapeutics Inc (NASDAQ:CTIC), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Colin Pettis02 mins

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, and the company’s Hsp90 inhibitor drug conjugates (HDC) will be presented at the 2014 Annual Meeting of the American Association of Cancer Research in San Diego, California. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stock…

Read More